| Literature DB >> 21955806 |
Yassir Sbitti1, Ismail Essaidi, Adil Debbagh, Habiba Kadiri, Mohamed Oukabli, Yassine Moussaid, Khaoula Slimani, Mohamed Fetohi, Hakim Elkaoui, Abderrahmane Albouzidi, Mohamed Mahi, Abdelmounaim Ait Ali, Mohamed Ichou, Hassan Errihani.
Abstract
We report here a 44-year-old Moroccan man with resectable gastric adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry who was treated with trastuzumab in combination with chemotherapy in perioperative setting. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab, oxaliplatin, and capecitabine. Afterwards, he received total gastrectomy with extended D2 lymphadenectomy without spleno-pancreatectomy. A pathologic complete response was obtained with a combination of trastuzumab and oxaliplatin and capecitabine. He received 3 more cycles of trastuzumab containing regimen postoperatively.We conclude that resectable gastric carcinoma with overexpression of the c-erbB-2 protein should ideally be managed with perioperative combination of trastuzumab with chemotherapy. Further research to evaluate trastuzumab in combination with chemotherapy regimens in the perioperative and adjuvant setting is urgently needed.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21955806 PMCID： PMC3204255 DOI： 10.1186/1477-7819-9-112
Source DB: PubMed Journal: World J Surg Oncol ISSN： 1477-7819 Impact factor: 2.754